Effect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore premorbid employment status
- PMID: 19441129
- DOI: 10.1002/mds.22622
Effect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore premorbid employment status
Abstract
Using a structured interview method, we sought to address the following questions regarding cervical dystonia (CD) and employment: (1) what is the frequency and severity of job impairment in CD; (2) what are the clinical features that contribute to job impairment; (3) how does the effectiveness of botulinum toxin (BTx) compare to oral medications in restoring employment status. In our population of 155 CD patients, employment was affected by CD in 53.3% (31.2% reduced hours or responsibilities, 3.3% changed to different job, 18.9% loss of employment) and 68.9% of patients reported reduced overall productivity. The likelihood of altered employment (P < 0.0006), reduced productivity (P < 0.0001), and seeking disability benefits (P < 0.003) was significantly associated with the presence of neck pain, but not type of employment, spasmodic head motions, or duration of CD symptoms before treatment with BTx. Treatment with BTx was more likely to improve employment status than oral medications (66.1 vs. 18.5%) and much more likely to restore full employment with normal productivity (12.9 vs. 0.0%). These findings suggest that employment status is frequently affected by CD, particularly in patients withneck pain. BTx is significantly more effective than oral medications in restoring premorbid employment status.
2009 Movement Disorder Society.
Similar articles
-
Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.Mov Disord. 2005 Dec;20(12):1604-9. doi: 10.1002/mds.20670. Mov Disord. 2005. PMID: 16114026 Clinical Trial.
-
BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).Mov Disord. 1997 Sep;12(5):772-5. doi: 10.1002/mds.870120526. Mov Disord. 1997. PMID: 9380065
-
Working capacity and cervical dystonia.Parkinsonism Relat Disord. 2010 Mar;16(3):215-7. doi: 10.1016/j.parkreldis.2009.07.006. Epub 2009 Aug 5. Parkinsonism Relat Disord. 2010. PMID: 19660976
-
Treatment of cervical dystonia with botulinum toxin.Mov Disord. 2004 Mar;19 Suppl 8:S109-15. doi: 10.1002/mds.20024. Mov Disord. 2004. PMID: 15027062 Review.
-
[Current status and prospects of medical therapy for dystonia].Rinsho Shinkeigaku. 2006 Nov;46(11):967-9. Rinsho Shinkeigaku. 2006. PMID: 17432235 Review. Japanese.
Cited by
-
Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact.Medicine (Baltimore). 2023 Jul 1;102(S1):e32403. doi: 10.1097/MD.0000000000032403. Medicine (Baltimore). 2023. PMID: 37499081 Free PMC article. Clinical Trial.
-
Treatment satisfaction with botulinum toxin: a comparison between blepharospasm and cervical dystonia.Patient Prefer Adherence. 2017 Sep 14;11:1555-1563. doi: 10.2147/PPA.S141060. eCollection 2017. Patient Prefer Adherence. 2017. PMID: 29066869 Free PMC article.
-
AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis.Clinicoecon Outcomes Res. 2015 Sep 9;7:441-9. doi: 10.2147/CEOR.S86355. eCollection 2015. Clinicoecon Outcomes Res. 2015. PMID: 26392782 Free PMC article.
-
The effectiveness of physiotherapy for cervical dystonia: a systematic literature review.J Neurol. 2014 Oct;261(10):1857-65. doi: 10.1007/s00415-013-7220-8. Epub 2014 Jan 12. J Neurol. 2014. PMID: 24413637
-
Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia.Tremor Other Hyperkinet Mov (N Y). 2013 May 17;3:tre-03-139-2924-1. doi: 10.7916/D8CF9NVD. Print 2013. Tremor Other Hyperkinet Mov (N Y). 2013. PMID: 23724362 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources